Immunome Valuation
| IMNM Stock | USD 22.49 0.05 0.22% |
At this time, the firm appears to be undervalued. Immunome retains a regular Real Value of $28.52 per share. The prevalent price of the firm is $22.49. Our model calculates the value of Immunome from evaluating the firm fundamentals such as Return On Asset of -0.46, return on equity of -0.93, and Shares Outstanding of 110.34 M as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Immunome's valuation include:
Price Book 9.7869 | Enterprise Value | Enterprise Value Ebitda (0.72) | Price Sales 266.8611 | Enterprise Value Revenue 239.1076 |
Undervalued
Today
Please note that Immunome's price fluctuation is not too volatile at this time. Calculation of the real value of Immunome is based on 3 months time horizon. Increasing Immunome's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Immunome stock is determined by what a typical buyer is willing to pay for full or partial control of Immunome. Since Immunome is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Immunome Stock. However, Immunome's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 22.49 | Real 28.52 | Target 34.67 | Hype 22.95 |
The intrinsic value of Immunome's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Immunome's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Immunome helps investors to forecast how Immunome stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Immunome more accurately as focusing exclusively on Immunome's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Immunome's intrinsic value based on its ongoing forecasts of Immunome's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Immunome's closest peers.
Immunome Cash |
|
Immunome Total Value Analysis
Immunome is currently estimated to have valuation of 2.31 B with market capitalization of 2.58 B, debt of 4.83 M, and cash on hands of 34.65 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Immunome fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.31 B | 2.58 B | 4.83 M | 34.65 M |
Immunome Investor Information
About 85.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 2.96. Immunome had not issued any dividends in recent years. Based on the measurements of operating efficiency obtained from Immunome's historical financial statements, Immunome is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Immunome Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Immunome has an asset utilization ratio of 3.76 percent. This suggests that the Company is making $0.0376 for each dollar of assets. An increasing asset utilization means that Immunome is more efficient with each dollar of assets it utilizes for everyday operations.Immunome Profitability Analysis
Based on the measurements of profitability obtained from Immunome's financial statements, Immunome may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Immunome's ability to earn profits and add value for shareholders.Net Loss | First Reported 2019-03-31 | Previous Quarter -43.4 M | Current Value -57.5 M | Quarterly Volatility 32.9 M |
For Immunome profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Immunome to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Immunome utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Immunome's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Immunome over time as well as its relative position and ranking within its peers.
Immunome Earnings per Share Projection vs Actual
The next projected EPS of Immunome is estimated to be -0.614575 with future projections ranging from a low of -0.815 to a high of -0.48. Immunome's most recent 12-month trailing earnings per share (EPS TTM) is at -2.96. Please be aware that the consensus of earnings estimates for Immunome is based on EPS before non-recurring items and includes expenses related to employee stock options.Immunome Earnings Estimation Breakdown
The calculation of Immunome's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Immunome is estimated to be -0.614575 with the future projection ranging from a low of -0.815 to a high of -0.48. Please be aware that this consensus of annual earnings estimates for Immunome is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.81 Lowest | Expected EPS | -0.48 Highest |
Immunome Earnings Projection Consensus
Suppose the current estimates of Immunome's value are higher than the current market price of the Immunome stock. In this case, investors may conclude that Immunome is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Immunome's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 13 | 62.56% | 0.0 | -0.614575 | -2.96 |
Immunome Ownership Allocation
Immunome has a total of 110.34 Million outstanding shares. The majority of Immunome outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Immunome to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Immunome. Please pay attention to any change in the institutional holdings of Immunome as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Immunome Profitability Analysis
The company reported the previous year's revenue of 9.04 M. Net Loss for the year was (292.96 M) with loss before overhead, payroll, taxes, and interest of (164.73 M).About Immunome Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Immunome. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Immunome based exclusively on its fundamental and basic technical indicators. By analyzing Immunome's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Immunome's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Immunome. We calculate exposure to Immunome's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Immunome's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 10.4 M | 10.9 M | |
| Pretax Profit Margin | (37.26) | (39.13) | |
| Operating Profit Margin | (38.90) | (40.84) | |
| Net Loss | (37.26) | (39.13) |
Immunome Current Valuation Indicators
Immunome's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Immunome's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Immunome, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Immunome's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Immunome's worth.When determining whether Immunome is a strong investment it is important to analyze Immunome's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Immunome's future performance. For an informed investment choice regarding Immunome Stock, refer to the following important reports: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Will Biotechnology sector continue expanding? Could Immunome diversify its offerings? Factors like these will boost the valuation of Immunome. Market participants price Immunome higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Immunome data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.96) | Revenue Per Share | Quarterly Revenue Growth 0.698 | Return On Assets | Return On Equity |
Understanding Immunome requires distinguishing between market price and book value, where the latter reflects Immunome's accounting equity. The concept of intrinsic value - what Immunome's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Immunome's price substantially above or below its fundamental value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Immunome's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.